Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
45.68
-0.83 (-1.78%)
At close: Nov 7, 2025, 4:00 PM EST
45.87
+0.19 (0.42%)
After-hours: Nov 7, 2025, 7:59 PM EST
Novo Nordisk Revenue
Novo Nordisk had revenue of 74.98B DKK in the quarter ending September 30, 2025, with 5.14% growth. This brings the company's revenue in the last twelve months to 315.60B, up 16.64% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
315.60B DKK
Revenue Growth
+16.64%
P/S Ratio
4.05
Revenue / Employee
4,080,247 DKK
Employees
77,349
Market Cap
200.71B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Abbott Laboratories | 43.84B |
NVO News
- 26 minutes ago - Novo Nordisk: Hold On Tightly As The Market Tests Your Faith - Seeking Alpha
- 1 day ago - Novo Nordisk will not increase its proposal to acquire Metsera, Inc. - GlobeNewsWire
- 1 day ago - Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk - CNBC
- 1 day ago - Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know - Seeking Alpha
- 2 days ago - Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE - GlobeNewsWire
- 2 days ago - Novo Nordisk shares fall after deal with Trump to slash obesity drug prices - Reuters
- 2 days ago - Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk - CNBC
- 2 days ago - Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits - Reuters